Sundry Photography/iStock Editorial via Getty Images Amazon ( AMZN ) Pharmacy is now offering Eli Lilly’s ( LLY ) recently approved weight loss pill, Foundayo, across nearly 3,000 cities and towns in the U.S. via its same-day delivery service, the company announced on Thursday. Cash-paying customers with a valid prescription can access the once-daily pill at $5 per day or $149 per month, while tho...
Sundry Photography/iStock Editorial via Getty Images Amazon ( AMZN ) Pharmacy is now offering Eli Lilly’s ( LLY ) recently approved weight loss pill, Foundayo, across nearly 3,000 cities and towns in the U.S. via its same-day delivery service, the company announced on Thursday. Cash-paying customers with a valid prescription can access the once-daily pill at $5 per day or $149 per month, while those with insurance can buy it at $1 per day or $25 per month, the e- commerce giant said. Soon after a medical appointment, patients can also purchase the GLP-1 therapy at in-office kiosks available at some of its One Medical locations. The company plans to expand its same-day delivery service to nearly 4,500 U.S. localities by the end of this year. The announcement came after Eli Lilly ( LLY ) said on Thursday that Foundayo, which was approved by the FDA earlier this month, will be available across U.S. retail pharmacies beginning today. More on Amazon, Eli Lilly 3 Reasons To Buy Eli Lilly Now Amazon: Ride AWS AI Workload Acceleration Optimism Amazon Vs. Starlink: The $9 Billion Globalstar Deal That Could Change Everything Eli Lilly launches new weight loss pill Foundayo in U.S. Amazon's chip unit's annual revenue run rate over $20B, discusses capex returns
CoreWeave Inc . is tapping the junk bond market after expanding a deal to supply artificial intelligence computing power to Meta Platforms Inc. The cloud infrastructure company intends to sell $1.25 billion of notes maturing in 2031 in a private offering, according to a statement . Proceeds will be used for general corporate purposes, including debt repayment. Initial price talk on the offering is...
CoreWeave Inc . is tapping the junk bond market after expanding a deal to supply artificial intelligence computing power to Meta Platforms Inc. The cloud infrastructure company intends to sell $1.25 billion of notes maturing in 2031 in a private offering, according to a statement . Proceeds will be used for general corporate purposes, including debt repayment. Initial price talk on the offering is for a yield in the low 10% range, a person familiar with the matter said. JPMorgan Chase & Co. , Morgan Stanley and Goldman Sachs Group Inc. are managing the sale, the person added, asking not to be identified because details are private. The offering adds to a wave of high-yield issuance from companies racing to fund the expensive buildout of artificial intelligence infrastructure, testing investors’ appetite for further exposure to the sector amid bubble fears and tolerance for risk as the Middle East conflict weighs on markets. “As spending on AI infrastructure continues to accelerate so does the need for additional debt funding,” Bloomberg Intelligence analysts Robert Schiffman and Alex Reid said in a note . Both Meta and CoreWeave are likely to continue to tap debt markets as their cloud capacity agreement expands, they added. “Though rising capital needs may pressure technicals, demand for tech-leader debt across high grade and high yield remains considerable.” CoreWeave said on Thursday that it will supply AI cloud capacity to the Facebook owner through December 2032 for about $21 billion, building on a previous $14.2 billion agreement. The deal sent the company’s stock up by 2.4% as of 8:47 a.m. in New York, before regular-trading hours. The firm — one of the so-called “neoclouds” businesses that rent out access to leading AI chips — has been a chief beneficiary of a race among major technology companies to build the most advanced AI models that has sent demand for computing demand soaring. CoreWeave sold junk bonds for the first time in May, raising $2 billion at ...
‘I see a lot of players come in and it’s too big for them’ Maguire feels he is ‘one of best defenders in both boxes’ Harry Maguire believes the harder times he has experienced at Manchester United would have broken many players and says he has seen teammates find the Old Trafford spotlight too big to handle. Maguire, who feels he is “arguably one of the best defenders in the world in both boxes”, ...
‘I see a lot of players come in and it’s too big for them’ Maguire feels he is ‘one of best defenders in both boxes’ Harry Maguire believes the harder times he has experienced at Manchester United would have broken many players and says he has seen teammates find the Old Trafford spotlight too big to handle. Maguire, who feels he is “arguably one of the best defenders in the world in both boxes”, this week signed a new one-year contract with the option of a further season. That extends a United career which began when the club paid a then world-record fee for a defender, £80m, to sign him from Leicester in 2019. Continue reading...
Firmus Technologies, the Australian AI data center startup, has secured a fresh $505 million investment backed by Nvidia (NVDA). This new funding pushes the company’s valuation to $5.5 billion ahead of its expected initial public offering (IPO). The investment also reflects strong demand for the large-scale computing facilities in the global AI market. Firmus Raises $505 Million to Expand AI Infra...
Firmus Technologies, the Australian AI data center startup, has secured a fresh $505 million investment backed by Nvidia (NVDA). This new funding pushes the company’s valuation to $5.5 billion ahead of its expected initial public offering (IPO). The investment also reflects strong demand for the large-scale computing facilities in the global AI market. Firmus Raises $505 Million to Expand AI Infrastructure Firmus’ latest $505 million funding round was led by global investment firm Coatue Managem
(RTTNews) - CoreWeave, Inc. (CRWV), a cloud infrastructure technology company, Thursday, announced an expanded long-term agreement with Meta Platforms, Inc. (META), the social media major, to provide AI cloud capacity through December 2032 for around $21 billion.
(RTTNews) - CoreWeave, Inc. (CRWV), a cloud infrastructure technology company, Thursday, announced an expanded long-term agreement with Meta Platforms, Inc. (META), the social media major, to provide AI cloud capacity through December 2032 for around $21 billion.
My top 10 things to watch Thursday, April 9 1. Stock futures are pointing to a lower open this morning as oil prices are rising. U.S. benchmark WTI crude is up 5% to over $99 a barrel. Will oil tanker traffic in the Strait of Hormuz resume? Will the ceasefire hold? Iran has already accused the U.S. of breaching it. 2. After yesterday's big relief rally, the S & P 500 has climbed 6.9% from the war-...
My top 10 things to watch Thursday, April 9 1. Stock futures are pointing to a lower open this morning as oil prices are rising. U.S. benchmark WTI crude is up 5% to over $99 a barrel. Will oil tanker traffic in the Strait of Hormuz resume? Will the ceasefire hold? Iran has already accused the U.S. of breaching it. 2. After yesterday's big relief rally, the S & P 500 has climbed 6.9% from the war-driven bottom on March 30. It's also just 2.8% below its record close on Jan. 27. Yesterday, the market showed you what's worth owning when things calm down. Labor market and inflation are key questions. We learned this morning that the Fed's preferred inflation gauge matched expectations in February, up 3% year over year when excluding food and energy. 3. Club name Meta Platforms and CoreWeave announced an expanded long-term agreement for AI computing capacity worth $21 billion . Meta needs all the compute it can get for things like Reels and its new AI models , and CoreWeave has the chips, including Nvidia' s forthcoming Vera Rubin platform. Clear signal that the AI boom hasn't faded. 4. JPMorgan upgraded Capital One to buy from and hold, naming the credit-card issuer its top pick in the consumer finance sector. The pullback in this Club stock has been frustrating, but JPMorgan sees limited downside from here unless "new tail risks emerge." When Capital One reports in less than two weeks, I want to see clear progress in realizing synergies from the Discover acquisition and learn more about its plans for payments startup Brex . 5. Hormel Foods was downgraded to hold from buy at JPMorgan, with analysts worried about margin headwinds for the maker of Spam and Skippy peanut butter. Packaged food stocks have been a graveyard. Hormel is down 27% over the past year, and its 5% dividend yield hasn't blunted the decline. With plans to buy Unilever's food business, McCormick is arguably the most interesting stock in this neighborhood. 6. Stifel upgraded Texas Instruments to buy fro...
England utility back Helena Rowland will start at inside centre in a much-changed team for their Women's Six Nations opener against Ireland at Allianz Stadium on Saturday.
England utility back Helena Rowland will start at inside centre in a much-changed team for their Women's Six Nations opener against Ireland at Allianz Stadium on Saturday.
FatCamera/E+ via Getty Images Thesis NovaBridge Biosciences ( NBP ) reported an FY25 GAAP EPS of about -$0.48. So, there have clearly been continued losses, with the company investing pretty heavily in clinical development. Now, even with the negative earnings, the company maintains a decent liquidity position with about $210.8 million in cash and short-term investments. We can expect this sum to ...
FatCamera/E+ via Getty Images Thesis NovaBridge Biosciences ( NBP ) reported an FY25 GAAP EPS of about -$0.48. So, there have clearly been continued losses, with the company investing pretty heavily in clinical development. Now, even with the negative earnings, the company maintains a decent liquidity position with about $210.8 million in cash and short-term investments. We can expect this sum to provide cash runway through to 2028. My upside thesis would hinge more on continued strong clinical validation of Givastomig. I expect this candidate's progression to be a big driver of the stock, particularly if the upcoming data confirms durable efficacy and clean safety. What we want is a smooth transition into a registrational Phase 3 and a potential accelerated approval pathway to add momentum to shares. If we do see this, it would likely drive a significant re-rating of the pipeline with the market starting to assign a much more meaningful value beyond the company’s current near-cash valuation that we're seeing now. NovaBridge Biosciences NovaBridge Biosciences F Y25 results NovaBridge reported FY25 results this week, and the company seems to still be in transition from a restructuring phase into capital-intensive clinical development. As you would then expect, there’s been a hefty increase in R&D spending, now $62.9 million, up from $21.8 million back in 2024. Now, this was mainly driven by acquisitions such as VIS-101 and Bridge Health assets, but they’ve also made some progress on a few of their lead programs. That being said, it would seem that management’s focus right now is strategic prioritisation of pipeline acceleration over near-term profitability. They reported a net loss from continuing operations of about $88.3 million, a lot wider than the year before. However, I don’t see this deterioration as unusual for a biotech firm entering mid-stage trials. As for spending, administrative expenses remained relatively controlled, rising only slightly to $31.4 milli...
Rocket Lab (NASDAQ: RKLB) just completed its 85th mission, further strengthening the case that the business is executing at a high level. But with options activity surging and expectations already elevated, the bigger opportunity may come down to whether the stock can still justi
Rocket Lab (NASDAQ: RKLB) just completed its 85th mission, further strengthening the case that the business is executing at a high level. But with options activity surging and expectations already elevated, the bigger opportunity may come down to whether the stock can still justi
After recent losses in trials related to social-media practices, the tech company began taking down ads on its apps meant to attract eligible plaintiffs.
After recent losses in trials related to social-media practices, the tech company began taking down ads on its apps meant to attract eligible plaintiffs.